BioNTech
NEWS
BioNTech and Medigene announced a global agreement to develop T-cell immunotherapies against cancer. The three-year collaboration will focus on multiple solid tumor targets.
It was noted early in the COVID-19 pandemic that the disease was peculiar — not only was it a respiratory disease, but it created hyper-immune responses.
Research Roundup for February 18
At this time, 73% of Americans are immune to Omicron, and it could rise to 80% by mid-March. For that and more COVID-19 news, continue reading.
BioNTech is opening one of the largest mRNA vaccines manufacturing facilities in the world to expand the availability of the COVID-19 vaccine.
With the Omicron surge waning, at least in the U.S., there is speculation that the COVID-19 pandemic may be in its end stages. Some experts, however, warn that this could be premature.
Although the Omicron surge appears to be waning in the U.S., the World Health Organization keeps an eye on four Omicron subvariants.
Pfizer indicated it will wait for the full data on a three-dose series of the vaccine for that population, believing it “may provide a higher level of protection in this age group.
The EMA’s safety committee has announced that they are reviewing reports of menstrual disorders after people received COVID-19 vaccinations from Pfizer-BioNTech and Moderna.
JOBS
IN THE PRESS